CORCencora, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Revenue
- $321.3B
- 9.3% YoY
- Operating margin
- 0.8%
- 11% YoY
- EBITDA
- $3.7B
- 13% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 0.6×
- $2.2B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear249% of net incomeCash flow under 80% of net income
- Dilutive SBCClear0% of revenueOver 10% of revenue
- Payouts exceed cash flowClear23% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear20% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B | 9.3% |
| Operating income | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B | 21% |
| Net income | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B | 3.0% |
| Operating cash flow | $2.7B | $2.7B | $3.9B | $3.5B | $3.9B | 11% |
| Capex | $438M | $496M | $458M | $487M | $668M | 37% |
| Stock-based comp | $100M | $93M | $125M | $148M | $148M | 0.0% |
| Buybacks | $82M | $484M | $1.2B | $1.5B | $435M | 71% |
| Dividends | $367M | $392M | $399M | $416M | $437M | 5.0% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $1M · 3
- Net
- −$1M
Pay vs performance
No pay-versus-performance disclosure yet.